SUN PHARMACEUTICAL INDUSTRIES LIMITED

Sun Pharma and Moebius Medical's MM-II (Large Liposomes of DPPC and DMPC) received FDA Fast Track designation for osteoarthritis knee pain treatment, with Phase 3 trials planned. The designation aims to expedite development and review of therapies addressing unmet medical needs.

Sun Pharmaceutical Industries and Moebius Medical received FDA Fast Track designation for MM-II (Large Liposomes of DPPC and DMPC) to treat osteoarthritis knee pain, with Phase 3 clinical trials planned.

A form with dropdowns for selecting state, zip code, and country, with Texas pre-selected as the state and the United States as the country.

Sun Pharma and Moebius Medical receive Fast Track designation for MM-II, a treatment for osteoarthritis knee pain, from the FDA. Phase 3 clinical trials are planned.

FDA approves Leqselvi (deuruxolitinib), an oral JAK inhibitor for severe alopecia areata treatment.

The precision medicine market, valued at $73.11 billion in 2023, is projected to grow to $118.08 billion by 2028, driven by rising cancer prevalence and strategic collaborations. It segments by technology, application, and end-use, with major players including Roche, Pfizer, and Novartis.